Tissue Modeling in Embryonic Stem (Es) Cell System
First Claim
Patent Images
1. Method of modeling and/or obtaining tissue or tissue-like structures comprising culturing an embryonic stem (ES) cell-derived first cell type in the presence of at least one embryonic second cell type;
- and allowing integration and alignment of said at least two cell types into tissue or tissue-like structures.
3 Assignments
0 Petitions
Accused Products
Abstract
Provided are embryonic stem (ES) cell-derived tissue modeling systems. In particular, systems for the de novo generation of tissue by parallel drug selection of cell types constituting the tissue of interest in one culture of differentiating ES cells is described as well as the use of such systems in transplantation and drug development.
-
Citations
81 Claims
-
1. Method of modeling and/or obtaining tissue or tissue-like structures comprising culturing an embryonic stem (ES) cell-derived first cell type in the presence of at least one embryonic second cell type;
- and allowing integration and alignment of said at least two cell types into tissue or tissue-like structures.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 26, 40, 41, 42, 45, 49, 63, 70, 71, 72, 73, 74, 75, 80)
-
18. A method for improving cardiac function in a mammal after a myocardial infarct, said method comprising the steps of:
-
(a) culturing undifferentiated mammalian embryonic stem (ES) cells comprising a resistance gene and a reporter gene under the control of the same cardiac-specific promoter in vitro in a culture medium containing the selective agent for the resistance gene under conditions allowing differentiation of said ES cells into cardiomyocytes;
(b) isolating said differentiated cardiomyocytes and/or eliminating non-differentiated cells, optionally along with cells differentiating towards irrelevant cell types from said cardiomyocytes in the course of differentiation;
(c) subsequently co-transplanting said cardiomyocytes with embryonic or ES cell-derived fibroblasts to at least a portion of the previously infarcted area of the heart tissue; and
(d) allowing said introduced cellular inoculum to engraft in situ as viable cells situated within the previously infarcted area of the heart tissue, wherein the engraftment results in improved cardiac function in said mammal. - View Dependent Claims (19, 20)
-
-
21. Method of modeling and/or obtaining tissue or tissue-like structures comprising the following steps:
-
(a) transfecting one or more multi- or pluripotent cells with recombinant nucleic acid molecules comprising a first and a second cell type-specific regulatory sequence operably linked to at least one selectable marker, wherein said second cell type is different from said first cell type;
(b) culturing the cells under conditions allowing differentiation of the cells; and
(c) isolating cells of at least two differentiated cell types and/or eliminating non-differentiated cells, optionally along with cells differentiating towards irrelevant cell types from cell types of interest that activate the selectable marker in the course of differentiation. - View Dependent Claims (22, 23, 24, 25, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 43, 44, 46, 47, 48, 50, 59, 60, 61, 62, 64, 65, 66, 67, 68, 69, 76, 77, 78, 79, 81)
-
-
51. A method for improving cardiac function in a mammal after a myocardial infarct, said method comprising the steps of:
-
(a) transfecting mammalian embryonic stem (ES) cells with a recombinant nucleic acid molecule comprising a resistance gene under the control of cardiac, fibroblast and/or endothelium-specific regulatory sequences, and optionally comprising one or more reporters under the same specific regulatory sequences;
(b) culturing said ES cells in vitro in a culture medium containing the selective agent for the resistance gene under conditions allowing differentiation of said ES cells into cardiomyocytes, fibroblasts and/or endothelial cells;
(c) eliminating from said differentiated cardiomyocytes, fibroblasts and/or endothelial cells non-differentiated cells, optionally along with cells differentiating towards irrelevant cell types;
optionally(d) allowing aligning and integration of said differentiating cardiomyocytes, fibroblasts and/or endothelial cells into cardiac-like tissue;
(e) subsequently co-transplanting said cardiomyocytes, fibroblasts and/or endothelial cells or said tissue to at least a portion of the previously infarcted area of the heart tissue; and
(f) allowing said introduced cells or tissue to engraft in situ as viable cells situated within the previously infarcted area of the heart tissue, wherein the engraftment results in improved cardiac function in said mammal. - View Dependent Claims (52, 53, 54, 55, 56, 57, 58)
-
Specification